Ampulla of Vater Carcinoma

P=N/A, N=182, Not yet recruiting, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital; Department of Gastroenterology, The First Medical Center of

P=N/A, N=60, Recruiting, The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University

However, the present results should be interpreted as exploratory and hypothesis-generating. Further large-scale studies are warranted to clarify the biological significance of these immune features and their potential therapeutic implications.

These findings suggest that current surveillance recommendations for individuals with LS should be re-evaluated. Lynch-Polyposis.

P=N/A, N=90, Recruiting, Minia University | Not yet recruiting --> Recruiting

P=N/A, N=320, Completed, State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital | Active, not recruiting --> Completed

P=N/A, N=90, Not yet recruiting, Minia University

However, it also reinforces the need for careful patient selection to avoid unnecessary surgical morbidity when the anticipated oncological benefit is limited. Overall, these findings emphasize the need for prospective, age-stratified studies to better define prognostic models and guide personalized therapeutic approaches for this distinct patient population.

P=N/A, N=268, Completed, Ruijin Hospital | Recruiting --> Completed | Phase classification: P3 --> PN/A | Trial completion date: Nov 2022 --> Feb 2025

P=N/A, N=420, Not yet recruiting, Alliance for Clinical Trials in Oncology

P2, N=54, Not yet recruiting, Yale University

Patients with advanced AC formed the "Descriptive cohort," while those treated with cisplatin-gemcitabine (CisGem) comprised the "CisGem-treated cohort." Among 534 trial participants, 28 (5.24%) had AC, and 17 received CisGem. Molecular profiling has revealed potentially actionable alterations, including HER2 amplification and KRAS mutations, supporting precision oncology approaches. This study provides the most comprehensive reference dataset to date for advanced AC treated with CisGem and emphasizes the importance of international collaboration and molecularly guided research to improve outcomes in this rare malignancy.